Virologic Suppression, Treatment Adherence, and Improved Quality of Life on a Once-Daily Efavirenz-Based Regimen in Treatment-Naïve HIV-1–Infected Patients Over 96 Weeks

REFERENCES

• Lucas GM, Wu AW, Cheever LW. Adherence to antiretrovi-ral therapy: an update of current concepts. Curr HIV/AIDS Rep. 2004;1(4):172–180.
   PubMedGoogle Scholar
• Roge BT, Barfod TS, Kirk O, et al. Resistance profiles and adherence at primary virological failure in three dif-ferent highly active antiretroviral therapy regimens: anal-ysis of failure rates in a randomized study. HIV Med. 2004;5(5):344–351.
   PubMed Web of Science ®Google Scholar
• Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral ther-apy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004;36(3):808–816.
   PubMed Web of Science ®Google Scholar
• Vervoort SC, Borleffs JC, Hoepelman Al, Grypdonck MH. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21(3):271–281.
   PubMed Web of Science ®Google Scholar
• Boyle BA, Jayaweera D, Witt MD, Grimm K, MaaJF, Seek-ins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regi-men improves adherence while maintaining viral suppres-sion. HIV Clin Trials. 2008;9(3):164–176.
   PubMed Web of Science ®Google Scholar
• Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev Anti Infect Ther. 2004;2(5): 671–684.
   PubMedGoogle Scholar
• Riddler SA, Haubrich R, DiRienzo G, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–2106.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Cohen C, Sax P. Improvement in quality of life (QoL) with once daily didanosine EC (DDI-EC), lamivudine (3TC) and efavirenz (EFV): 24 week interim results from the DART I trial. Presented at: Annual Meeting of the Infectious Disease Society of America; October 9–12; 2003; San Diego, CA.
   Google Scholar
• Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qua/ Life Res. 1997;6(6):481–493.
   PubMed Web of Science ®Google Scholar
• Badia X, Podzamczer D, Garcia M, Lopez-Lavid CC, Consiglio E. A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQ0L-HIV Validation Group. Medical Outcomes Study HIV Health Survey. AIDS. 1999;13(13):1727–1735.
   PubMed Web of Science ®Google Scholar
• Felizarta F, DeJesus E, Jayaweera D, et al. High adherence with once-daily efavirenz-based regimens: 96 week results from the Daily Antiretroviral Therapy I & ll (DART I & II) tri-als. Proceedings of the National Institute of Mental Health/ International Association of Physicians in AIDS Care Inter-national Conference on HIV Treatment Adherence; March 8–10, 2006; Jersey City, NJ, USA. Abstract 228.
   Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to pro-tease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
   PubMed Web of Science ®Google Scholar
• Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37(8)1112–1118.
   Web of Science ®Google Scholar
• Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29\(suppl 1):52–10.
   Google Scholar
• Battaglioli-DeNero AM. Strategies for improving patient adherence to therapy and long-term patient outcomes. J Assoc Nurses AIDS Care. 2007;18(1 suppl):S17—S22.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adher-ence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibi-tors. Clin Infect Dis. 2005;40(1):158–163.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Airoldi M, Kleinloog HD, et al. Effects of adher-ence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or P1-treated patients. HIV Clin Trials. 2007;8(5):282–292.
   PubMed Web of Science ®Google Scholar
• Rosenblum M, Deeks SG, Van Der Laan MJ, Bangsberg DR. The risk of virologic failure decreases with duration of continuous viral suppression for adherence levels above 50%. Presented at: the 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Mon-treal, Canada. Abstract 583.
   Google Scholar
• Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169–177.
   PubMed Web of Science ®Google Scholar
• Berenguer J, Gonzalez J, Ribera E, et al. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivu-dine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis. 2008;47(8)1 083–1092.
   PubMed Web of Science ®Google Scholar
• Santos J, Palacios R, Lozano F, et al. Long-term assess-ment of didanosine, lamivudine, and efavirenz in antiret-roviral-näive patients: 3-year follow-up. AIDS Res Hum Retroviruses. 2008;24(1):24–26.
   PubMed Web of Science ®Google Scholar
• Sanchez-Conde M, Palacios R, Sanz J, et al. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: the ELADI study. AIDS Res Hum Retrovi-ruses. 2007;23(10)1237–1241.
   Web of Science ®Google Scholar